Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Emma M. Ernst"'
Publikováno v:
Journal of Clinical Oncology. 35:e16548-e16548
e16548 Background: Family history (FH) is a well-documented risk factor for prostate cancer (PCa). Previously, germline pathogenic variants (PVs) have been identified in metastatic PCa. The goal of this study was to fully evaluate cancer FH and asses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a23bb42657b199b3566f2a78af560b52
https://doi.org/10.1200/jco.2017.35.15_suppl.e16548
https://doi.org/10.1200/jco.2017.35.15_suppl.e16548
Autor:
Emma M. Ernst, Oliver Sartor, Patrick Cotogno, Brian E. Lewis, Joshua Schiff, Elisa Ledet, Charlotte Manogue
Publikováno v:
Journal of Clinical Oncology. 35:234-234
234 Background: Cell free DNA (cfDNA) present in plasma of cancer pts can reflect tumoral alterations. Genomic alterations in cfDNA alter prognosis and abiraterone/enzalutamide resistance in mCRPC. The goal of this evaluation was to characterize AR a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa4a288ccfcec69dbb577e905117f894
https://doi.org/10.1200/jco.2017.35.6_suppl.234
https://doi.org/10.1200/jco.2017.35.6_suppl.234
Publikováno v:
Journal of Clinical Oncology. 35:225-225
225 Background: African American (AA) race and family history (FH) of prostate cancer (PCa) increase the incidence and mortality of PCa. The goal of this study was to assess and compare FH in AA and Caucasian (C) men. Methods: During June 2015 throug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::28b03f2ba7af9e1e2bd08fc751334894
https://doi.org/10.1200/jco.2017.35.6_suppl.225
https://doi.org/10.1200/jco.2017.35.6_suppl.225
Autor:
A. Oliver Sartor, Ashwin Vasudevamurthy, Brian E. Lewis, Patrick Cotogno, Emma M. Ernst, Jonathan L. Silberstein, Allison H. Feibus, Jeffrey R. Guccione, Elisa Ledet, Charlotte Manogue
Publikováno v:
Journal of Clinical Oncology. 35:e574-e574
e574 Background: Abiraterone (Abi) and enzaleutamide (Enza) are first-line agents for the treatment of metastatic castrate-resistant prostate cancer (mCRPC). Primary resistance is well-documented, but little data exists for rapid treatment responders
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fff6c05bdf01244cd2faf27e4fbf8ab7
https://doi.org/10.1200/jco.2017.35.6_suppl.e574
https://doi.org/10.1200/jco.2017.35.6_suppl.e574
Publikováno v:
Journal of Clinical Oncology. 35:272-272
272 Background: Family history (FH) is a well-documented risk factor for prostate cancer (PCa). Certain cancers (Ca) are also shown to co-segregate in families. This study evaluated Ca FH in PCa patients (pts) and the impact of FH on clinical covaria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc7ad5730bc4643c9d154cd0a0fa8040
https://doi.org/10.1200/jco.2017.35.6_suppl.272
https://doi.org/10.1200/jco.2017.35.6_suppl.272
Autor:
Brian E. Lewis, Joshua Schiff, Elisa Ledet, Oliver Sartor, Emma M. Ernst, Cathryn E. Garvey, Shuwen Lin
Publikováno v:
Journal of Clinical Oncology. 35:185-185
185 Background: In prostate cancer (PCa), germline pathogenic variants have previously been underestimated. PCa patients (pts) with DNA repair defects have a higher percentage of non-PCa family history (FH) with the most common cancers being derived
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::038e41b046a3c34e733cb86ef97969c2
https://doi.org/10.1200/jco.2017.35.6_suppl.185
https://doi.org/10.1200/jco.2017.35.6_suppl.185
Publikováno v:
Journal of Clinical Oncology. 35:201-201
201 Background: Taste alterations are a common yet frequently under-assessed problem in cancer patients. Health-related quality-of-life (HRQOL) instruments for prostate cancer (PCa) patients (pts) do not assess taste despite these hypothetically bein
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a01990ea013dacbef7df92689aa0065c
https://doi.org/10.1200/jco.2017.35.6_suppl.201
https://doi.org/10.1200/jco.2017.35.6_suppl.201
Publikováno v:
Journal of Clinical Oncology. 34:279-279
279 Background: Prostate cancer is one of the most common adult malignancies. Two well characterized risk factors for prostate cancer (PCa) are family history (FH) and race. The goal of this study was to distinguish the influence of family history an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95f5a3b153b95823076498ca9a7cbd1a
https://doi.org/10.1200/jco.2016.34.2_suppl.279
https://doi.org/10.1200/jco.2016.34.2_suppl.279
Publikováno v:
Journal of Clinical Oncology. 34:246-246
246 Background: African-Americans (AA) have the highest rate of prostate cancer (PCa) incidence and mortality. Studies have shown higher rates of chronic prostate inflammation in AAs compared to Caucasians (CA). In order to better understand racial d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::823c5178b6102f027575ab063bc6bc06
https://doi.org/10.1200/jco.2016.34.2_suppl.246
https://doi.org/10.1200/jco.2016.34.2_suppl.246